OncoTherapy Science (4564) · RiskRestated
Risk that drug candidates will not match pharmaceutical companies' R&D needs
First written in FY2017. 1 of 2 entries say "Restated". Latest entry: FY2018.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Uncertainty over the Formation and Terms of Pharmaceutical Out-Licensing and In-Licensing PartnershipsA theme 7 companies write about · 7 as a headwind · 0 as a tailwind
4 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2018RestatedAnnual report
「There is no guarantee that the drug candidates and other substances provided by the Group will meet the research and development needs of pharmaceutical companies and others, or that partnerships for each drug candidate will progress as anticipated by the Group.」
The company continues to disclose the risk that drug candidates may not meet pharmaceutical companies' needs and that partnerships may fail to progress as planned. - FY2017First statedAnnual report
「There is no guarantee that the drug candidates and other substances provided by the Group will meet the research and development needs of pharmaceutical companies and others, or that partnerships for each drug candidate will progress as anticipated by the Group.」
The company has explicitly identified for the first time as a risk the possibility that drug candidates may not meet pharmaceutical companies' needs and that partnerships for individual candidates may not progress as anticipated.